NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Latigo Biotherapeutics, Inc. (LTGO) Stock Analysis

Latigo Biotherapeutics, Inc. (LTGO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LTGO

$16.34

+$1.09 (+7.15%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LTGO with… →

LTGO Key Statistics

As of Oct 21, 2026
Trading
Open
$15.45
Previous Close
$15.25
Day's Range
15.18–16.78
52-Week Range
13.50–25.93
Volume
173.76K
Valuation
Market Cap
$1.08B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.52
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$109.17M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
66.30M
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
365.04K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Latigo Biotherapeutics, Inc. (LTGO) has a market capitalization of $1.08B.

In fiscal 2025, LTGO reported revenue of $0.00.

LTGO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$109.17M—
2024$0.00−$61.18M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$110.39M−$109.17M—
2024$0.00—−$63.45M−$61.18M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Latigo Biotherapeutics, Inc. (LTGO) carries a market capitalisation of $1.08B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 66.

Over the past 52 weeks the price has ranged from $13.50 to $25.93. LTGO last closed at $16.34 on October 21, 2026. That is +$1.09 (+7.15%) against the previous close. The latest close sits 21.04% above that 52-week low.

Financial Health

In fiscal 2025, Latigo Biotherapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $109.17M. Earnings per share on a trailing basis come to −2.52.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

The record shows no dividend for LTGO.

2026 is still running; the total return is −10.47% year to date.

Peer Comparison

Latigo Biotherapeutics, Inc. (LTGO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Latigo Biotherapeutics, Inc. LTGO $1.08B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Latigo Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.

Visit website →